NRX Pharmaceuticals NRXP
NASDAQ NRXP
$2.90 +0.05 (+1.75%)
At close: Oct 2, 2026 · 4:00 PM EDT

NRX Pharmaceuticals (NRXP) Return on Sales [ROS] (2025 - 2026)

Updated

NRX Pharmaceuticals (NRXP) recorded Return on Sales [ROS] of -590.83% in Q2 2026, down 159.74 percentage points from the prior quarter.

Analysis

NRX Pharmaceuticals (NRXP) Return on Sales [ROS] (2025 - 2026) Analysis & Trends

On a TTM basis, NRX Pharmaceuticals' Return on Sales [ROS] came in at -580.71% as of Jun 30, 2026; for FY2025, it came in at -1324.41%.

  • Quarterly Return on Sales [ROS] has ranged from -1662.81% in Q3 2025 to -431.09% in Q1 2026 over the past five years.
  • Per Business Quant, the preceding three quarters came in at -431.09% (Q1 2026), -470.40% (Q4 2025) and -1662.81% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 NRX Pharmaceuticals 125.16 Mn 76.75 Mn 426,000.00 -590.83%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -590.83%
Mar 31, 2026 -431.09%
Dec 31, 2025 -470.40%
Sep 30, 2025 -1,662.81%
API Access

NRX Pharmaceuticals Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=NRXP&period=max&api_key=YOUR_API_KEY